Get the Stockscreener App
43.82
2.62%
1.12
Ionis Pharmaceuticals Inc stock is traded at $43.82, with a volume of 1.04M.
It is up +2.62% in the last 24 hours and down -7.26% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
See More
Previous Close:
$42.70
Open:
$43.58
24h Volume:
1.04M
Relative Volume:
0.38
Market Cap:
$7.28B
Revenue:
$1.06B
Net Income/Loss:
$-326.58M
P/E Ratio:
-20.84
EPS:
-2.1022
Net Cash Flow:
$-977.73M
1W Performance:
+1.20%
1M Performance:
-7.26%
6M Performance:
-42.96%
1Y Performance:
-39.47%
1-Day Range:
$43.42
$44.71
1-Week Range:
$42.08
$45.72
52-Week Range:
$42.08
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
43.82 | 7.28B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
508.46 | 128.88B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.99 | 95.01B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.59 | 82.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.61 | 53.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.06 | 42.09B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-26 | Initiated | BMO Capital Markets | Market Perform |
| Jul-16-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-19-26 | Initiated | Citigroup | Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Apr-10-26 | Resumed | Raymond James | Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Oct-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-26-25 | Upgrade | Goldman | Sell → Neutral |
| Sep-03-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-31-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-01-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - Zacks Investment Research
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal - Zacks Investment Research
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. - The Motley Fool
Ionis Pharmaceuticals (NasdaqGS:IONS) Stock Forecast & Analyst Predictions - Simply Wall Street
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs - Zacks Investment Research
A kidney disease can progress to kidney failure in up to half of patients within 20 years. Ionis' drug met its trial goal. - Stock Titan
A rare genetic disease drug trial met its main goal. Otsuka plans FDA talks. - Stock Titan
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool
IONS Stock Heads Toward Biggest Single-Day Slump In Over 5 Years – Retail Calls It ‘Opportunity Of A Lifetime’ - Stocktwits
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax Bio - Barchart.com
Ionis Has Its First Neurology Launch, But Can Zanvastro Justify Its $285,000 Price? - Yahoo Finance
Precision Trading with Ionis Pharmaceuticals Inc. (IONS) Risk Zones - Stock Traders Daily
Rx Rundown: GSK, Novartis, Ionis Pharmaceuticals and more - Medical Marketing and Media
Ethan Weiss: Two Trial Flops End the "Genetics Is Undefeated" Era in Heart Drugs - finance.biggo.com
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure? - Yahoo Finance
Ionis at Wells Fargo healthcare conference: launches offset setbacks - investing.com
Ionis at Wells Fargo healthcare conference: launches offset setbacks By Investing.com - Investing.com Canada
IONS: Strategic approvals and strong launches drive growth, with pipeline poised for further milestones - TradingView
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making. - Yahoo Finance
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue? - Zacks Investment Research
IONS Maintained by Barclays -- Price Target Lowered to $85.00 - GuruFocus
Ionis Pharmaceuticals (IONS) Institutional Ownership 2026 $IONS - MarketBeat
BofA Securities Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $91 - Moomoo
Raymond James cuts Ionis Pharmaceuticals price target on trial miss - Investing.com
Raymond James cuts Ionis Pharmaceuticals price target on trial miss By Investing.com - Investing.com Canada
Raymond James cuts Ionis Pharmaceuticals price target on trial miss By Investing.com - Investing.com India
Raymond James Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $84 - Moomoo
Retatrutide clears BLA bar while Wainua stumbles in busy July for trials - BioWorld News
IONS Maintained by Goldman Sachs -- Price Target Lowered to $56 - GuruFocus
BMO cuts Ionis Pharmaceuticals stock price target on drug failure By Investing.com - Investing.com Canada
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades - Seeking Alpha
BMO cuts Ionis Pharmaceuticals stock price target on drug failure By Investing.com - Investing.com UK
Ionis Pharmaceuticals gets $85 price target des... - Pluang
H.C. Wainwright cuts Ionis stock price target to $100 on pelacarsen removal - Investing.com
Canaccord cuts Ionis stock price target to $85 on pelacarsen trial miss - Investing.com
H.C. Wainwright cuts Ionis stock price target to $100 on pelacarsen removal - Investing.com Canada
Canaccord cuts Ionis stock price target to $85 on pelacarsen trial miss - Investing.com Canada
Needham reiterates Ionis stock rating after trial failure By Investing.com - Investing.com India
Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss - TipRanks
IONS Maintained by HC Wainwright & Co. -- Price Target Lowered to $100 - GuruFocus
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Why Is Novartis Stock Falling Today?Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty - Benzinga
Ionis Pharmaceuticals Shares Fall After Pelacarsen Phase 3 Trial Misses Primary Endpoint - Yahoo Finance
Why is Ionis Pharmaceuticals stock tumbling today? By Investing.com - Investing.com India
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander DiseaseSlideshow (NASDAQ:IONS) 2026-09-07 - Seeking Alpha
Ionis Drug Wins FDA Approval as First Alexander Disease Treatment - Yahoo
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal - Zacks Investment Research
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Evaluating A 51.72% Upside Potential - DirectorsTalk Interviews
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) - BioSpace
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ionis Pharmaceuticals Inc Stock (IONS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hayden Michael R | Director |
Jul 31 '26 |
Buy |
51.60 |
5,000 |
258,000 |
24,000 |
| BERTHELSEN SPENCER R | Director |
Jul 15 '26 |
Option Exercise |
0.00 |
5,220 |
0 |
161,233 |
| HERMAN JOAN E | Director |
Jul 15 '26 |
Option Exercise |
0.00 |
5,220 |
0 |
51,306 |
| Diaz Allene M. | Director |
Jul 07 '26 |
Option Exercise |
47.11 |
10,111 |
476,329 |
13,922 |
| Diaz Allene M. | Director |
Jul 07 '26 |
Sale |
85.42 |
10,111 |
863,637 |
3,811 |
| Diaz Allene M. | Director |
Jul 07 '26 |
Proposed Sale |
85.42 |
10,111 |
863,637 |
0 |
| Kordasiewicz Holly B. | Officer |
Jul 07 '26 |
Proposed Sale |
84.30 |
1,287 |
108,494 |
0 |
| BENNETT C FRANK | Officer |
Jul 07 '26 |
Proposed Sale |
84.95 |
67,386 |
5,724,724 |
0 |
| Kordasiewicz Holly B. | EVP, Chief Development Officer |
Jul 07 '26 |
Sale |
84.30 |
362 |
30,517 |
22,096 |
| BENNETT C FRANK | EVP, Chief Scientific Officer |
Jul 07 '26 |
Sale |
85.46 |
15,000 |
1,281,930 |
0 |
0.17%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):